HAIER BIOMEDICAL(SH:688139) Sou Hu Cai Jing·2025-06-18 11:15Core Viewpoint - Haier Biomedical's stock closed at 30.28 yuan, down 1.62%, with a rolling PE ratio of 28.38 times and a total market value of 9.628 billion yuan, indicating a lower valuation compared to the industry average [1][3]. Company Overview - Qingdao Haier Biomedical Co., Ltd. focuses on providing optimal user experiences for life science users, including pharmaceutical and biological enterprises, research institutions, and healthcare users, forming two main business segments: life sciences and medical innovation [2]. - The company offers comprehensive digital solutions represented by smart laboratories, digital hospitals, and smart public health, with key products including low-temperature storage boxes, automated biological sample storage, and various automated medication products [2]. Financial Performance - In Q1 2025, the company reported revenue of 689 million yuan, a year-on-year increase of 0.30%, and a net profit of 110 million yuan, reflecting a year-on-year decrease of 19.88%, with a gross profit margin of 48.35% [3]. - The company's PE ratio is 28.38, while the industry average is 49.10, indicating a significant valuation gap [3]. Shareholder Information - As of March 31, 2025, Haier Biomedical had 12,793 shareholders, a decrease of 453 from the previous period, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1].